Medtronic moves for patent infringement
litigation to resume
DUBLIN, March 21,
2024 /CNW/ -- Medtronic (NYSE:MDT), the global leader
in healthcare technology, today announced that the Patent Trial and
Appeal Board (PTAB) of the U.S. Patent and Trademark Office has
affirmed the validity of claims in two of its patents in an ongoing
patent infringement lawsuit filed by Medtronic against
Axonics over sacral neuromodulation (SNM) technologies.
Cumulatively, the PTAB has now upheld the validity of five of the
Medtronic patents at issue in this lawsuit.
Medtronic will now ask the federal court in the Central District
of California, where Medtronic's
patent infringement lawsuit is pending, to lift its stay on the
lawsuit and proceed to trial on the five valid and affirmed patents
so Medtronic can present its case in front of a jury.
"It's now past time for Axonics to stand up in a court of law
and take responsibility for its unauthorized use and infringement
of Medtronic's intellectual property," said Mira Sahney, president of the pelvic health
business in the neuroscience portfolio at Medtronic. "We respect
the intellectual property of innovators, and our patent system
exists to benefit society by encouraging the kind of innovation
that Medtronic invests in. We are pleased with the PTAB's decision,
and we are confident that the evidence at trial will show that
Axonics improperly used and profited from Medtronic's patented
technology."
Medtronic also filed a complaint with the U.S. International
Trade Commission (ITC) along with a parallel action in the U.S.
District Court for the District of Delaware to block Axonics from improperly
importing and selling products that infringe two additional
Medtronic patents related to the MRI compatibility of implantable
medical devices.
About Medtronic
Bold thinking. Bolder actions. We are
Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global
healthcare technology company that boldly attacks the most
challenging health problems facing humanity by searching out and
finding solutions. Our Mission — to alleviate pain, restore health,
and extend life — unites a global team of 95,000+ passionate people
across more than 150 countries. Our technologies and therapies
treat 70 health conditions and include cardiac devices, surgical
robotics, insulin pumps, surgical tools, patient monitoring
systems, and more. Powered by our diverse knowledge, insatiable
curiosity, and desire to help all those who need it, we deliver
innovative technologies that transform the lives of two people
every second, every hour, every day. Expect more from us as we
empower insight-driven care, experiences that put people first, and
better outcomes for our world. In everything we do, we are
engineering the extraordinary. For more information on Medtronic
(NYSE:MDT), visit www.Medtronic.com and follow Medtronic on
LinkedIn.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated results.
Contacts:
Laurel Hood
Ryan
Weispfenning
Public Relations
Investor Relations
+1-763-514-0249
+1-763-505-4626
View original content to download
multimedia:https://www.prnewswire.com/news-releases/us-patent-office-rejects-axonics-latest-challenge-to-medtronic-patents-302096380.html
SOURCE Medtronic plc